GRAIL, Inc. (GRAL)
140.00
+2.63
(+1.91%)
USD |
NASDAQ |
Oct 13, 14:59
GRAIL Debt to Equity Ratio : 0.0359 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0359 |
| March 31, 2026 | 0.0204 |
| December 31, 2025 | 0.0213 |
| September 30, 2025 | 0.0262 |
| June 30, 2025 | 0.0269 |
| March 31, 2025 | 0.0266 |
| December 31, 2024 | 0.0272 |
| September 30, 2024 | 0.0279 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0282 |
| March 31, 2024 | 0.0214 |
| December 31, 2023 | 0.0231 |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| September 30, 2020 | 0.0967 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Moderna, Inc. | 0.1904 |
| Twist Bioscience Corp. | 0.21 |
| Prime Medicine, Inc. | 2.825 |
| Kailera Therapeutics, Inc. | 0.0091 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.844B |
| Total Liabilities (Quarterly) | 301.03M |
| Shareholders Equity (Quarterly) | 2.543B |
| Current Ratio | 10.95 |
| Net Debt Paydown Yield | -0.18% |